

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

NiQuitin Minis 4 mg Lozenges

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each lozenge contains 4 mg nicotine (as nicotine resinate).

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Compressed Lozenge

White to off white biconvex oval lozenge. "NIC4" is debossed onto one face.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

NiQuitin Minis 4 mg Lozenges relieve and/or prevent craving and nicotine withdrawal symptoms associated with tobacco dependence. They are indicated to aid smokers wishing to quit or reduce prior to quitting, to assist smokers who are unwilling or unable to smoke, and as a safer alternative to smoking for smokers and those around them.

NiQuitin Minis 4 mg Lozenges are indicated in pregnant and lactating women making a quit attempt.

NiQuitin Minis 4 mg Lozenges should preferably be used in conjunction with a behavioural support programme.

4.2 Posology and method of administration

Posology:

Users should make every effort to stop smoking completely during treatment with NiQuitin Minis.

The strength of lozenge to be used will depend on the smoking habits of the individual.

NiQuitin Minis 4 mg Lozenges are suitable for smokers who smoke more than 20 cigarettes a day.

Behavioural therapy advice and support will normally improve the success rate.

Adults (18 year and over)

Abrupt cessation of smoking

Use the lozenges whenever there is an urge to smoke.

Sufficient lozenges should be used each day, usually 8-12, up to a maximum of 15.

Continue use for up to six weeks to break the habit of smoking, then gradually reduce lozenge use. When daily use is 1-2 lozenges, use should be stopped.

To help stay smoke free after treatment, users may take a lozenge in situations when they are strongly tempted to smoke.

Those who have quit smoking but are having difficulty discontinuing using the lozenges are recommended to seek additional help and advice from a healthcare professional.

Gradual cessation of smoking:

For smokers who are unwilling or unable to quit abruptly.

Use a lozenge whenever there is a strong urge to smoke in order to reduce the number of cigarettes smoked as far as possible and to refrain from smoking as long as possible.

The number of lozenges a day is variable and depends on the patient's needs. Nonetheless it should not exceed 15 lozenges per day.

If a reduction in cigarette consumption has not been achieved after 6 weeks of treatment, a healthcare professional should be consulted.

Reduced tobacco consumption should lead to complete cessation of smoking. This should be attempted as soon as possible. When the number of cigarettes has been reduced to a level from which the user feels able to quit completely, then start on the schedule for "abrupt cessation" as given above.

If the attempt to stop smoking completely has not been started within 6 months after the beginning of treatment, it is recommended to consult a healthcare professional.

Reduction in smoking:

For smokers who wish to cut down with no immediate plans to quit.

Use a lozenge whenever there is a strong urge to smoke in order to reduce the number of cigarettes smoked as far as possible and to refrain from smoking as long as possible. Users should be encouraged to stop smoking completely as soon as possible.

The number of lozenges a day is variable and depends on the patient's needs. Nonetheless it should not exceed 15 lozenges per day.

If users are still feeling the need to use the lozenges on a regular basis 6 months after the start of treatment and have still been unable to undertake a permanent quit attempt, then it is recommended to seek additional help and advice from a healthcare professional.

Temporary Abstinence

Use a lozenge every 1-2 hours to control troublesome withdrawal symptoms including craving. Users should not take more than 15 lozenges per day. Users should be encouraged to stop smoking completely as soon as possible. If users are still feeling the need to use the lozenges on a regular basis 6 months after the start of treatment and have still been unable to undertake a permanent quit attempt, then it is recommended to seek additional help and advice from a healthcare professional.

Paediatric population:

Adolescents (12-17 years) should follow the schedule of treatment for abrupt cessation of smoking as given above, but as data are limited, duration of use of NRT in this age group is restricted to 12 weeks. Where adolescents are not ready or able to stop smoking abruptly, advice from a healthcare professional should be sought.

NiQuitin Minis 4 mg Lozenges are contraindicated in children under 12 years of age.

Method of administration

One lozenge should be placed in the mouth and allowed to dissolve. Periodically, the lozenge should be moved from one side of the mouth to the other, and repeated, until the lozenge is completely dissolved (approximately 10 minutes). The lozenge should not be chewed or swallowed whole.

Users should not eat or drink while a lozenge is in the mouth.

4.3 Contraindications

NiQuitin Minis 4 mg Lozenges are contraindicated in:

- Hypersensitivity to nicotine or any of the excipients listed in section 6.1;
- Children under the age of 12 years
- Non-smokers.

4.4 Special warnings and precautions for use

The risks associated with the use of nicotine replacement therapy (NRT) are substantially outweighed in virtually all circumstances by the well-established dangers of continued smoking.

Dependent smokers hospitalized with a recent myocardial infarction, severe cardiac arrhythmias, unstable or worsening angina including Prinzmetal's angina, uncontrolled hypertension or recent cerebrovascular accident and/or who are considered to be haemodynamically unstable should be encouraged to stop smoking with non-pharmacological interventions (such as counselling).

If this fails, NiQuitin Minis Lozenges may be considered, but as data on safety in this patient group are limited, initiation should only be under medical supervision. Once patients are discharged from hospital they can use NRT as normal. If there is a clinically significant increase in cardiovascular or other effects attributable to nicotine, the lozenge dose should be reduced or discontinued.

- *Diabetes Mellitus:* Blood glucose levels may be more variable when stopping smoking, with or without NRT as catecholamines released by nicotine can affect carbohydrate metabolism, so it is important for diabetics to closely monitor their blood glucose levels while using this product.
- *Allergic reactions:* susceptibility to angioedema and urticaria.

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

- *Renal and hepatic impairment:* Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.
- *Phaeochromocytoma and uncontrolled hyperthyroidism:* Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.
- *Gastrointestinal Disease:* Swallowing of nicotine may exacerbate symptoms in persons suffering from active oesophagitis, oral or pharyngeal inflammation, gastritis, gastric ulcer or peptic ulcer and oral NRT preparations should be used with caution in these conditions. Ulcerative stomatitis has been reported.
- *Seizures:* Use with caution in subjects taking anti-convulsant therapy or with a history of epilepsy as cases of convulsions have been reported in association with nicotine.

Danger in small children: Doses of nicotine tolerated by adult and adolescent smokers can produce severe toxicity in small children that may be fatal. Products containing nicotine should not be left where they may be misused, handled or ingested by children.

Stopping smoking: Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs catalysed by CYP 1A2 (and possibly by CYP 1A1).

When a smoker stops this may result in a slower metabolism and a consequent rise in blood levels of such drugs.

Transferred dependence: Transferred dependence is rare and is both less harmful and easier to break than smoking dependence.

Sodium: This medicinal product contains less than 1 mmol (23 mg) per lozenge that is to say essentially sodium-free.

4.5 Interaction with other medicinal products and other forms of interaction

No clinically relevant interactions between nicotine replacement therapy and other drugs have definitely been established, however nicotine may possibly enhance the haemodynamic effects of adenosine.

Smoking cessation itself may require the adjustment of some drug therapy.

4.6 Fertility, pregnancy and lactation

Pregnancy

Smoking during pregnancy is associated with risks such as intra-uterine growth retardation, premature birth or stillbirth. Stopping smoking is the single most effective intervention for improving the health of both the pregnant smoker and her baby. The earlier abstinence is achieved the better.

Ideally smoking cessation during pregnancy should be achieved without NRT. However, for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt. The risk of using NRT to the fetus is lower than that expected with tobacco smoking, due to lower maximal plasma nicotine concentration and no additional exposure to polycyclic hydrocarbons and carbon monoxide.

However, as nicotine passes to the fetus affecting breathing movements and has a dose dependent effect on placental/fetal circulation, the decision to use NRT should be made as early on in the pregnancy as possible. The aim should be to use NRT for only 2-3 months.

Intermittent dosing products may be preferable as these usually provide a lower daily dose of nicotine than patches. However, patches may be preferred if the woman is suffering from nausea during pregnancy (see section 4.2).

Breast-feeding

Nicotine from smoking and NRT is found in breast milk. However, the amount of nicotine the infant is exposed to from NRT is relatively small and less hazardous than the second-hand smoke they would otherwise be exposed to.

Ideally smoking cessation during pregnancy should be achieved without NRT. However, for women unable to quit on their own, NRT may be recommended by a healthcare professional to assist a quit attempt.

Using intermittent dose NRT preparations, compared with patches, may minimize the amount of nicotine in the breast milk as the time between administrations of NRT and feeding can be made as long as possible. Women should try to breastfeed just before they take the product (see section 4.2).

Fertility

There are no human data on the effects of nicotine on fertility. In animal studies, nicotine has been shown to adversely affect both the male and female reproductive systems (see section 5.3). The clinical relevance of such effects on fertility are unknown.

4.7 Effects on ability to drive and use machines

NiQuitin Minis have no or negligible influence on the ability to drive and use machines. However, users of nicotine replacement products should be aware that smoking cessation can cause behavioral changes.

4.8 Undesirable effects

NRT can cause adverse reactions similar to those associated with nicotine administered in other ways, including smoking. These may be attributed to the pharmacological effects of nicotine, which are dose dependent. At recommended doses NiQuitin Minis 4 mg Lozenges have not been found to cause any serious adverse effects. Excessive consumption of NiQuitin Minis by those who have not been in the habit of inhaling tobacco smoke could possibly lead to nausea, faintness or headaches.

Certain symptoms which have been reported such as depression, irritability, anxiety, increased appetite and insomnia may be related to withdrawal symptoms associated with smoking cessation. Subjects quitting smoking by any means could expect to suffer from headache, dizziness, sleep disturbance, increased coughing or a cold.

Adverse reactions are listed below by system organ class and frequency. Frequencies are defined as: Very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) and very rare ($< 1/10,000$), not known (cannot be estimated from the available data).

System Organ Class and Frequency	Adverse Reaction/Event
<u>Infections and infestations</u> <i>Common</i>	Pharyngitis
<u>Blood and lymphatic system disorders</u> <i>Uncommon</i>	Gingival bleeding; nosebleed
<u>Immune system disorders</u> <i>Very rare</i>	Anaphylactic reactions
<i>Not known</i>	Hypersensitivity
<u>Psychiatric disorders</u> <i>Common</i>	Insomnia***, anxiety, irritability, increased appetite, anger, aggravated anxiety
<i>Uncommon</i>	Abnormal dreaming; abnormal hunger, mood swings, wakefulness
<u>Nervous system disorders</u> <i>Common</i>	Headache***, dizziness***
<i>Uncommon</i>	Localised numbness; parageusia, metallic taste, taste perversion
<i>Not known</i>	Seizures*, tremor
<u>Cardiac disorders</u> <i>Uncommon</i>	Aggravated palpitations, palpitations, tachycardia
<u>Vascular disorders</u> <i>Uncommon</i>	Vascular disorder, flushing, skin flushed
<u>Respiratory, thoracic and mediastinal disorders</u> <i>Common</i>	Coughing***
<i>Uncommon</i>	Laryngismus, aggravated asthma, lower respiratory tract infection, nasal irritation; throat irritation, nasal congestion
<i>Not known</i>	Dyspnoea
<u>Gastrointestinal disorders</u> <i>Very common</i>	Nausea
<i>Common</i>	Vomiting, dyspepsia**, heartburn, indigestion, hiccup, mouth irritation, mouth

<p><i>Uncommon</i></p> <p><i>Not known</i></p>	<p>ulceration, tongue ulceration, diarrhoea, belching, flatulence, dry mouth, constipation</p> <p>Peptic ulcer, dysphagia, aggravated dyspepsia, gastroesophageal reflux, hiatus hernia, oesophagitis, eructation, buccal mucosa ulceration, borborygmus, dry lips, dry throat, tongue disorder, tooth ache</p> <p>Salivary hypersecretion</p>
<p><u>Skin and subcutaneous tissue disorders</u></p> <p><i>Uncommon</i></p> <p><i>Not known</i></p>	<p>Erythema, itching, rash, skin reaction localized, increased sweating</p> <p>Angioedema</p>
<p><u>Musculoskeletal, connective tissue and bone disorders</u></p> <p><i>Uncommon</i></p>	<p>Jaw pain</p>
<p><u>Renal and urinary disorders</u></p> <p><i>Uncommon</i></p>	<p>Nocturia</p>
<p><u>General disorders and administration site conditions</u></p> <p><i>Uncommon</i></p> <p><i>Not known</i></p>	<p>Overdose effect, pain, leg pain, oedema legs</p> <p>Asthenia***, fatigue***, malaise***, influenza like illness***</p>

**observed in users taking anti-convulsant therapy or with a history of epilepsy.*

***individuals with a tendency to experience indigestions may suffer initially from minor degrees of indigestion or heartburn if the 4 mg dose is used - slower chewing in the case of gum or the use of the 2 mg dose (if necessary, more frequently) will usually overcome this problem.*

****these events may also be due to withdrawal symptoms following smoking cessation.*

•

Paediatric population (12-17 years inclusive)

There are no specific adverse event data for this population. However, the frequency, type and severity of adverse reactions in adolescents are likely to be the same as adults, based upon a pharmacokinetic study demonstrating a similar pharmacokinetic profile in adolescents compared to adults.

•

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

The minimum lethal dose of nicotine in a non-tolerant man has been estimated to be 40 to 60 mg. Even small quantities of nicotine may be dangerous in children and may prove fatal. Suspected nicotine poisoning in a child should be considered a medical emergency and treated immediately.

Symptoms

Signs and symptoms of an overdose from nicotine lozenges would be expected to be the same as those of acute nicotine poisoning, including pallor, cold sweat, salivation, nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness, disturbed hearing and vision, tremor, mental confusion and weakness. Prostration, hypotension, respiratory failure, rapid or weak or irregular pulse, circulatory collapse and convulsions (including terminal convulsions) may ensue with large overdoses.

Management

In the event of an overdose (e.g. too many lozenges ingested) the user should seek medical attention immediately. All nicotine intake should cease immediately and the patient be treated symptomatically. Artificial respiration with oxygen should be instituted if necessary. Activated charcoal reduces the gastrointestinal absorption of nicotine.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in nicotine dependence.

ATC Code: N07B A01

Mechanism of Action

Nicotine is an agonist at nicotine receptors in the peripheral and central nervous system and has pronounced CNS and cardiovascular effects. When consumed in tobacco products, it has been shown to be addictive and abstinence is linked to craving and withdrawal symptoms. These craving and withdrawal symptoms include urge to smoke, depressed mood, insomnia, irritability, frustration or anger, anxiety, difficulty in concentrating, restlessness and increased appetite or weight gain. Cravings and other symptoms of nicotine withdrawal are at their most intense during the first few weeks of a quit attempt, diminishing thereafter. The lozenges replace some of the nicotine provided by tobacco and clinical studies measuring intensity of cravings and other withdrawal symptoms have been shown to alleviate these symptoms when they are at their most intense.

5.2 Pharmacokinetic properties

Absorption

NiQuitin Minis Lozenges dissolve completely in the oral cavity, and the entire amount of nicotine contained in the lozenge becomes available for buccal absorption or ingestion (swallowing). The complete dissolution of NiQuitin Minis Lozenges is typically achieved in 10 minutes. The peak plasma concentrations of nicotine achieved after a single dose are approximately 10.8 ng/ml. When dosed every 1.5 hours, the steady state peak and trough concentrations are 26.0 and 19.7 ng/ml respectively. Ingestion of NiQuitin Minis Lozenges not following dosing instructions (chewed, retained in the mouth, and swallowed; chewed and immediately swallowed) does not result in faster or higher absorption, but a substantial amount of nicotine (80-93%) is still absorbed.

Distribution

As the plasma protein binding of nicotine is low (4.9-20%), the volume of distribution of nicotine is large (2.5 l/kg). The distribution of nicotine to tissue is pH dependent, with the highest concentrations of nicotine found in the brain, stomach, kidney and liver.

Biotransformation

Nicotine is extensively metabolised to a number of metabolites, all of which are less active than the parent compound. The metabolism of nicotine primarily occurs in the liver, but also in the lung and kidney. Nicotine is metabolised primarily to cotinine but is also metabolised to nicotine N'-oxide. Cotinine has a half-life of 15-20 hours and its blood levels are 10 times higher than nicotine. Cotinine is further oxidized to *trans*-3'-hydroxycotinine, which is the most abundant metabolite of nicotine in the urine. Both nicotine and cotinine undergo glucuronidation.

Elimination

The elimination half-life of nicotine is approximately 2 hours (range 1 - 4 hours). Total clearance for nicotine ranges from approximately 62 to 89 l/hr. Non-renal clearance for nicotine is estimated to be about 75% of total clearance. Nicotine and its metabolites are excreted almost exclusively in the urine. The renal excretion of unchanged nicotine is highly dependent on urinary pH, with greater excretion occurring at acidic pH.

5.3 Preclinical safety data

The general toxicity of nicotine is well known and taken into account in the recommended posology. Nicotine was not mutagenic in appropriate assays. The results of carcinogenicity assays did not provide any clear evidence of a tumorigenic effect of nicotine. In studies in pregnant animals, nicotine showed maternal toxicity, and consequential mild fetal toxicity. Additional effects included pre- and postnatal growth retardation and delays and changes in postnatal CNS development.

Effects were only noted following exposure to nicotine at levels in excess of those which will result from recommended use of NiQuitin Mini Lozenges.

Studies in female rodents have shown that nicotine can decrease the number of oocytes in the fallopian tubes, decrease the concentration of serum estradiol, and result in a number of changes to the ovaries and uterus. Studies in male rats have shown that nicotine can decrease testis weight, cause a reversible decrease in Sertoli cell numbers with impairment of spermatogenesis, and result in a variety of changes in the epididymis and vas deferens. Effects on fertility have not been established.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol

Sodium alginate

Xanthan gum

Potassium bicarbonate

Calcium polycarbophil

Sodium carbonate anhydrous

Acesulfame potassium

Mint Flavour

Magnesium Stearate

Sucralose

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

30 months

6.4 Special precautions for storage

Do not store above 25°C. Store in the original package.

6.5 Nature and contents of container

Child resistant polypropylene tablet container/cap incorporating a molecular sieve desiccant (sodium aluminosilicate) and containing 20 lozenges.

Packs may contain 1, 3 or 5 tablet containers in a blister card or 5 tablet containers in a cardboard box.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Omega Pharma Ltd.
1st Floor
32 Vauxhall Bridge Road
London, SW1V 2SA
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 02855/0330

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

04/08/2023

10 DATE OF REVISION OF THE TEXT

04/08/2023